- Kymera is an R&D-heavy company, but its pipeline is so early stage, nobody knows how to value this company.
- The company’s platform is called PEGASUS, which matches E3 ligases with harmful proteins in order to design bifunctional small molecules which degrade the harmful, disease-causing proteins.
- Kymera’s industry partners include Sanofi (SNY) and Vertex (VRTX). The Sanofi partnership started in 2020 with $150mn in upfront payment. The deal is valued at $2bn in potential milestone payments plus tiered royalties.
- Its latest stage candidate is in phase 1. Known as KT-474, this molecule is, according to the company, “a potent, highly selective, orally bioavailable IRAK4 degrader, for the treatment of IL-1R/TLR-driven conditions and diseases with high unmet medical need
- In June 2021, Kymera announced positive interim results from the Single Ascending Dose (SAD) portion of the Phase 1 clinical trial of KT-474, demonstrating the first degrader proof-of-mechanism in targeted protein degradation in a randomized, placebo-controlled healthy volunteer study
Upcoming Catalysts
Phase 1: KT-474 Hidradenitis suppurativa / atopic dermatitis
- Phase 1 multiple ascending dose (MAD) data reported potent, marked IRAK4 reduction in peripheral blood mononuclear cells (PBMC) at doses substantially lower than those required in the single ascending dose (SAD), noted December 16, 2021. Phase 1 data to be presented on December 14, 2022. Phase 2 trial planned.
Phase 1:KT-413 - (IRAKIMiD)nDiffuse large B-cell lymphoma (DLBCL)111111111111
- Phase 1 first patient dosed noted June 15, 2022. Phase 1 data due in 4Q 2022.
Phase 1: KT-333 - (STAT3) Peripheral T-cell Lymphoma (PTCL)
- Phase 1 first patient dosed June 15, 2022. Phase 1 data due in 4Q 2022.
All the data read outs have the potential to be major binary event and will make or break the Company
"We look forward to the upcoming presentation on the Phase 2 VERITAC trial with ARV-471 at the San Antonio Breast Cancer Symposium in December, and Arvinas is well-positioned as we move into 2023.”
https://www.sabcs.org/ (Dec 6-10)
Other IRAK4 inhibitors failed:
- Pfizer’s IRAK4 inhibitor PF-06650833 was canned by the company after it failed to have any beneficial impact on HS patients.
- Curis’s Irak-4 inhibitor emavusertib was also put on a clinical hold by the FDA in two separate indications.
